{"id":923428,"date":"2026-01-04T16:03:04","date_gmt":"2026-01-04T21:03:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/"},"modified":"2026-01-04T16:03:04","modified_gmt":"2026-01-04T21:03:04","slug":"crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/","title":{"rendered":"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Jan.  04, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XtXbZriU0j0vT82_gZt21KRf60-_KTJQaIsoAfzWK47AoMUTV3ls2F0CLJAfrKxRb032wrn_q3juTCOs2cBTxunjKEKwxB3Ysi_2c5wnHx_PC0JuzV9_bZjV5xbdKU5e\" rel=\"nofollow\" target=\"_blank\">Crinetics Pharmaceuticals, Inc.<\/a> (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY\u2122 (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia.<\/p>\n<p align=\"justify\">\n        <strong>Conference Call and Webcast Details<\/strong><br \/>\n        <br \/>Management will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P82EZS53TYpLmHIJcHEk0HjE5Uu-y5SODS4RKc00cNk3AHiWzdug_wlEi7XFhPyXYeAERiWrmdJhgYf6uI_bo5EhwCGX1M84Z6a-pTQjQyGvZeIe-fBh2pZ-EXOv7lHEpWBt2Wxyc7Elz2_BGfBDUdOAuRJg6UAY1cKXknh5SkHY_Jq6dR4NDFDlMtojPdI-jrix37n6JcAdhFlWDpj910NEUzppr6ahYIuF-AodaZ79BzoPnJoWyRYPCQd-A_W5lAjYiIfbTLzjLFL2dkKInNCkkjGY2sVn5shDIqVy7Fq9ckRNKeh5JjcuPj3ut7JZIP0VWdygx1jfueLcScRFSPuFYvd73DFbuyey_xd_kxdPzkdRlN8VvzLXxXg3KkKyu2-SyB7hMPu7wtwP6UOZzYRD-Fgjia5veHre6aqJo4zv2mLg1veKlsm-PQH4s2RCtB6dmsWfIvsU9ezyAyBWn6TmC2tsJZL90MY3RfppJlhcRPFWIsKO5WKhnHrPJENiIhuPvRrAz_hiVUqpQloaL6vCxJ4Gllke6twvYQ-xzgUD_Wfph-PQuKYEmFyipzw-uNr3Y8utyvueRng0RN506ddKDKRnOcZZX3GzsDKlcjIuHq7N4JlUroz3JRY0TtafFan3eBgWT4T_KRx0v4BIEMH-AOrsOLBrZkoFQgqXc5ZyLf77Tx5IJD8NdRJQLnFAaqK3tM8ZvDLd3p2LKrG-FxWwn0g7uIM6aYczZ_ca-EFMt1ybVwe-y8rkzK2CfbjsSaD2Hk55gVxRzZjasJkx1QHeOTvxZgLHTZxfwcF5h3mXitH5I0HM6e5pA60rDTCaRYdH87C_ziQI7Kv18NnKdg==\" rel=\"nofollow\" target=\"_blank\">click here<\/a>. The archived webcast will also be accessible on the Events &amp; Presentations page in the Investors section of the Crinetics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UMBm2OoU3-EiSfBTE5vTWJdX8bHuAOb2y0KYtbWXcKubJzXRJKOR-HXrCeaOAdUu1j0OcwfiYMPAwLCGVb_Q58Q-IvqaSsRTpBPBQS4yryOG7isVPa5QQy5idwA9yVKs\" rel=\"nofollow\" target=\"_blank\">www.crinetics.com\/events<\/a>. To participate, please dial 1-833-470-1428 (domestic) or 1-646-844-6383 (international) and refer to Access Code 640078.<\/p>\n<p align=\"justify\">\n        <strong>ABOUT CRINETICS PHARMACEUTICALS <\/strong><br \/>\n        <br \/>Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.<\/p>\n<p align=\"justify\">Crinetics\u2019 lead product, PALSONIFY\u2122 (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and\/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics\u2019 deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing\u2019s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves\u2019 disease (including Graves\u2019 hyperthyroidism and Graves\u2019 orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Gayathri Diwakar<br \/>Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tO4tHSfBTs07cBDdtoXtL-JftcNXJL1cI9NAY7yarOnMQodB0j1k6uA3JI9EneXsyGCrurA7_RqPgV7hd4LijNsLvYERnzs3WLDCDaVeH8M=\" rel=\"nofollow\" target=\"_blank\">gdiwakar@crinetics.com<\/a><br \/>(858) 345-6340<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Natalie Badillo<br \/>Head of Corporate Communications <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Of8AcdQ1K1MkYudQ4Bbw755Sspg_i8o51SCUgqsfjovL_xPPPe4C80vaoah3CTLThmFS2zlwa1ZUMY6NkmOUisvw1gP-cehy9pArcx3mafI=\" rel=\"nofollow\" target=\"_blank\">nbadillo@crinetics.com<\/a><br \/>(858) 345-6075<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2JkOTJlZDYtZDUzYi00ODdkLWI2MzItZmZhODhhYTlhMjBiLTExMDEzODYtMjAyNi0wMS0wNC1lbg==\/tiny\/Crinetics-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY\u2122 (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast Details Management will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events &amp; Presentations page in the Investors section of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-923428","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY\u2122 (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast Details Management will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events &amp; Presentations page in the Investors section of the &hellip; Continue reading &quot;Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-04T21:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia\",\"datePublished\":\"2026-01-04T21:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/\"},\"wordCount\":374,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/\",\"name\":\"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=\",\"datePublished\":\"2026-01-04T21:03:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/","og_locale":"en_US","og_type":"article","og_title":"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Market Newsdesk","og_description":"SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY\u2122 (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast Details Management will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events &amp; Presentations page in the Investors section of the &hellip; Continue reading \"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-04T21:03:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia","datePublished":"2026-01-04T21:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/"},"wordCount":374,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/","name":"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=","datePublished":"2026-01-04T21:03:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ2NyM3MzQzNDc1IzIwODk4MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=923428"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923428\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=923428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=923428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=923428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}